Eli Lilly is trading 3.1% up now at $1222.14 after the UK medicines regulator authorized Foundayo for weight management and type 2 diabetes.
- The UK is the first European country to approve the pill.
- The authorization strengthens confidence in Lilly’s oral obesity-drug rollout, although Foundayo is not currently available through the NHS.
- The broader healthcare sector is also supporting the advance.